# EDGAR Filing Document

**Accession Number:** 0001787297
**File Stem:** 0001104659-26-066956
**Filing Date:** 2026-5
**Character Count:** 6590
**Document Hash:** 556ca293645aa8bb0e1fb2ce92dee202
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-066956.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0001104659-26-066956

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260521

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Passage BIO, Inc.
- **CENTRAL INDEX KEY:** 0001787297
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822729751
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39231
- **FILM NUMBER:** 261026355

**BUSINESS ADDRESS:**
- **STREET 1:** ONE COMMERCE SQUARE
- **STREET 2:** 2005 MARKET STREET, 39TH FLOOR
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103
- **BUSINESS PHONE:** 2678660312

**MAIL ADDRESS:**
- **STREET 1:** ONE COMMERCE SQUARE
- **STREET 2:** 2005 MARKET STREET, 39TH FLOOR
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103

?xml version='1.0' encoding='ASCII'? PASSAGE BIO, INC._May 21, 2026

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 21, 2026**

## PASSAGE BIO, INC.
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39231** | **82-2729751** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(CommissionFile Number)** | **(IRS EmployerIdentification No.)** |

---

---

| | |
|:---|:---|
| **Address Not Applicable**<sup>1</sup> | **Zip Code Not Applicable**<sup>1</sup> |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(267) 866-0311**

**(Registrant's telephone number, including area code)**

**One Commerce Square2005 Market Street, 39**<sup>th</sup> **Floor**

**Philadelphia, PA** 

 **(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 Par Value Per Share | PASG | The Nasdaq Stock Market LLC<br>(Nasdaq Capital Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

<sup>1</sup> We are a remote-only company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act and Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to our principal executive offices may be directed to P.O. Box 7, Hopewell, New Jersey 08525.

------

**Item 1.02 Termination of a Material Definitive Agreement.**

*Gemma - Research, Collaboration and License Agreement Termination*

On May 21, 2026, Passage Bio, Inc. (the "***Company***") provided written notice to Gemma Biotherapeutics, Inc. ("***Gemma***") of termination of the research, collaboration and license agreement, dated July 31, 2024, by and between Gemma and the Company (as amended, the "***Gemma Collaboration Agreement***"), which termination will be effective in accordance with the terms of the Gemma Collaboration Agreement.

Pursuant to the Gemma Collaboration Agreement, (i) Gemma conducted certain preclinical and Investigational New Drug-enabling work for the Company's active research program in Huntington's disease and a currently paused research program in Temporal Lobe Epilepsy and (ii) Gemma granted the Company options to conduct mutually-agreed research programs in four new central nervous system indications.

The foregoing description of the terms of the Gemma Collaboration Agreement is qualified in its entirety by reference to the full text of the agreement, a copy of which was filed with the Securities and Exchange Commission as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q on November 13, 2024.

*2005 Market Street Lease Agreement Termination*

On May 22, 2026, the Company and Commerce Square Partners – Philadelphia Plaza, L.P. (the "***Landlord***") entered into a lease termination agreement (the "***Termination Agreement***") with respect to that certain lease agreement dated April 10, 2020 between the Company and Landlord (the "***2005 Market Street Lease Agreement***"). Pursuant to the Termination Agreement, the Company agreed to pay the Landlord a termination fee of $2.3 million.

Pursuant to the 2005 Market Street Lease Agreement, the Company had leased approximately 37,000 square feet of office space. This lease commenced in February 2021 and was set to expire in December of 2031. In August 2023 and September 2023, the Company entered into two sublease agreements, for certain periods of time, which subleased substantially all of the office space under the 2005 Market Street Lease Agreement.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PASSAGE BIO, INC.** | **PASSAGE BIO, INC.** |
| Date: May 27, 2026 | By: | /s/ Kathleen Borthwick |
|  |  | Kathleen Borthwick |
|  |  | Chief Financial Officer |

---